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Introduction
Nonischemic DCM is a primary cardiac disease characterized by
decreased contractility and dilatation of the left and/or right ventri-
cle in the presence of normal coronary arteries.1,2 In DCM, the
interstitium is altered with increased collagen content,1-10 leading to
diastolic dysfunction.11 However, it has been very difficult to
noninvasively evaluate the severity of this disease.
In recent years, myocardial viability imaging with delayed con-
trast enhancement has become widely accepted for the detection
and characterization of myocardial infarction and myocardial fi-
brosis. Scars and fibrosis are depicted as areas of high signal inten-
sity on DE MR images. DE MR imaging is becoming a diagnostic
standard for evaluation of myocardial damage with high spatial
resolution in various myocardial diseases. This technique has also
been used for patients with DCM. According to previous reports,
myocardial fibrosis and disarray can show enhancement on DE
MR images.1,12,13
In patients with DCM, 123I-MIBG scintigram images show ab-
normalities such as a reduced delayed H/M ratio, heterogeneous
distribution of MIBG within the myocardium, and increased MIBG
washout from the heart. 123I-MIBG scintigrams have been re-
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Objective: The purpose of this study was to compare delayed enhancement (DE) cardiac magnetic resonance (MR) imaging with the indine-
123-metaiodobenzylguanidine (123I-MIBG) scintigram for measurement of left ventricular (LV) contraction function in patients with dilated
cardiomyopathy (DCM).
Materials and methods: DCM patients (n=29: mean age,51.9years; seven women) were evaluated by both DE cardiac MR imaging and 123I-
MIBG scintigram. In all patients biopsy specimen showed disarray of the myocardium that was consistent with DCM. DE cardiac MR images
were acquired using a two-dimensional segmented inversion-recovery prepared gradient-echo sequence (TI=250msec) 15minutes after intra-
venous administration of 0.1 mmol/kg gadolinium.
The average CNR per slice (aCNR) for the LV myocardium was calculated.
123I-MIBG scintigram was acquired at 15minutes and 3 hours (delayed imaging) after intravenous administration of 123I-MIBG (111MBq). The
heart-to-mediastinum radioactivity ratio (H/M ratio) and washout rate (WR) was calculated. We evaluated the relationships between aCNR, WR,
delayed H/M ratio, and the contraction function of the LV.
Results: In MR imaging, mean aCNR was significantly higher in the low LV ejection fraction (LVEF<25%) group (n=11, 6.6±3.6) than in the
high LVEF ( 25%) group (n=18, 2.4±2.9). However, with the 123I-MIBG scintigram, delayed H/M and WR were not significantly different be-
tween high (delayed H/M ratio ; 1.7±0.3, WR; 37.6±14.5) and low (delayed H/M ratio; 1.7±0.2, WR; 38.2±14.2) LVEF groups.
Conclusions: DE MR imaging reflects the contraction function of the LV in patients with DCM, which may be related with myocardial fibrosis.
DE MR imaging may be more useful to evaluate the contraction function of LV than 123I-MIBG scintigram.
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ported to be useful for evaluation of LV function in patients with
heart failure.14-19
We have compared DE cardiac MR imaging with 123I-MIBG
scintigrams for measurement of LV contraction function. We also
compared these modalities in regard to performance status of pa-
tients based on New York Heart Association (NYHA) classifica-
tion. The purpose of this study was to investigate whether quanti-
fication by DE cardiac MR imaging or myocardial 123I-MIBG
scintigraphy was useful for noninvasively evaluating myocardial
contraction function in patients with DCM.
Materials and methods
patients
Twenty-nine patients with DCM (mean age =51.9, seven women)
were enrolled in this study. The diagnosis of nonischemic DCM
was made according to the World Health Organization/International
Society and Federation of Cardiology criteria.18,19 None of the pa-
tients had clinical symptoms or signs of ongoing myocarditis.
Patients with significant coronary artery disease (>50% diameter
luminal stenosis in any coronary artery) or LVEF >56% were ex-
cluded from this study. Other exclusion criteria were the presence
of any contraindications of cardiac MR (CMR), significant valvular
disease, hypertrophic cardiomyopathy, any evidence of infiltrative
heart disease, or treatment with beta-blockers before the imaging
study. In all of the patients, specimens obtained by myocardial bi-
opsy showed disarray, varying degrees of interstitial fibrosis, and/-
or myocyte hypertrophy of the myocardium, which were consistent
with DCM. Five patients had been treated with angiotensin-
converting enzyme inhibitors, four with diuretics, three with digi-
talis, and two with angiotensin receptor blockades. All patients
gave written informed consent, and the protocol was approved by
the medical ethics committee.
DE MRI Imaging
All patients were studied in the supine position using a 1.5-T
CMR system (Signa CV/i, GE Healthcare, Milwaukee, Wis) with
a 4-element phased-array surface coil. The CMR study consisted of
cine steady-state free-precision imaging (repetition time, 3.4 ms;
echo time, 1.2 ms; in-plane spatial resolution, 1.6x2 mm) of LV
function and DE imaging. All images were acquired with ECG gat-
ing and breath-holding. DE images were obtained in 8 to 14 match-
ing short axes (8-mm thickness with 0-mm spacing). DE images
were acquired by using a two-dimensional segmented inversion-
recovery prepared gradient-echo sequence (repetition time msec/echo
time msec/inversion time msec, 9.8/4.4/250; typical voxel size,
1.3x1.16 x8 mm3) 15 minutes after intravenous administration of
0.2 mmol/kg gadolinium-DTPA (Schering, Berlin, Germany).
Cardiac 123I-MIBG scintigraphy
In all patients, 123I-MIBG scintigrams were acquired at 15minutes
and 3 hours after intravenous administration of 123I-MIBG (111MBq).
Anterior planar and single photon emission computed tomography
(SPECT) images were obtained by triple-head gamma camera
(Prism 3000; Picker-International) with a low-energy high-resolution
collimator. The gamma camera was rotated over a 120°arc with an
acquisition time of 40s per image at 5°intervals for each view.
Energy discrimination was provided by a 20% window centered at
159 keV. 64×64 pixel matrix.
Data Analysis
All MR imaging post processing was performed by a single ob-
server (E.S., with over 10 years of experience in cardiac MR imag-
ing). LVEF was derived from cine images using the MASS soft-
ware package (MEDIS, Leiden, the Netherlands). On the basis of
LVEF results, patients were divided into a low LVEF group
(<25%) and a high LVEF group ( 25%).2
For quantification of DE images, we evaluated the signal inten
sity (SI) of the myocardium of the LV and skeletal muscles near the
heart using a workstation (Advantage Windows 4.2; GE Healthcare).
For the LV myocardium, we manually traced epicardial and
endocardial borders including the papillary muscles, and ROIs
were placed in each slice. We traced and used the entire LV myo-
cardium (total ROI in myocardium; 151. 3 - 301.2 cm2) as an ROI
in all subjects. For the skeletal muscles, we manually traced the
borders of the deltoid muscle, and ROIs were placed in the same
slice (total ROI in muscle; 361.0-816.97 cm2) (Figure 1). If the del-
2
Figure 1. For measuring signed intensity of the myocardium of the LV (H)
and the skeletal muscles (M), we manually traced regions of interest (ROI)
in each slice.
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toid muscle was too small to trace or was not seen in the slice, we
traced the borders of the trapezius muscle.
The calculated SI values were divided by background noise (air)
to measure the average signal-to-noise ratio (aSNR) and aCNR per
slice in each patient.
Background noise was evaluated as follows: three ROIs (each
ROI; approximately 20cm2, 19.3-21.4cm2) were placed on the ante-
rior extracorporeal background (one at the top, one in the middle,
and one at the bottom of the field of view), and the mean SI ±
standard deviation of noise was measured in all three regions.
First, the SNR of the LV myocardium was calculated using the
following equation for each slice: SNR=SImyo/SDair, where
SImyo is SI of the myocardium and SDair is the standard deviation
of air.
The CNR for the LV myocardium was calculated using the fol-
lowing equation for each slice: CNR=(SImyo - SImusc)/SDair,
where SImusc is the SI of the muscle.
The total values of SI, SNR, and CNR were then calculated for
each patient. The average SI (aSI), aSNR, and aCNR per slice for
the LV myocardium were calculated using the following equation
for each individual: aSI =total value of SI/ total number of slices
in each patient. aSNR = total value of SNR/ total number of slices
in each patient. aCNR = total value of CNR/ total number of slices
in each patient.
To evaluate myocardial MIBG uptake, the whole H/M ratio was
determined from the delayed anterior planar 123I-MIBG image.
The H/M ratio was calculated by drawing ROIs around the LV
myocardium and in the upper mediastinum and measuring the av-
erage counts per pixel in each ROI.
The global WR was calculated using the following formula:
{([H]-[M])early - ([H]-[M])delayed} / ([H]-[M])early x 100(%),
where [H] = mean count per pixel in the LV and [M] = mean count
per pixel in the upper mediastinum.
Statical analysis
All values are expressed as the mean ±SD. Statistical analysis
was performed on clinical and morphological variables with Mann-
Whitney's U-test for continuous variables. Pearson correlation co-
efficients were used to examine the correlation of LVEF with aSI,
aSNR, and aCNR. Correlation coefficient values of 0.4-1.0 were
considered to indicate a correlation.18 In all tests, P < 0.05 was con-
sidered significant.
All statistical analyses were performed using a commercially
available software (SPSS, release 11.5; SPSS, Chicago,III).
Results
Table 1 shows the mean LVEF, number of slices of the myocar-
dium, aSI of the myocardium, aSNR, aCNR(Figure 2 and Figure
3), delayed H/M ratio, and WR(Figure 4) in both low and high EF
groups. Mean aSI of the myocardium, aSNR, delayed H/M ratio,
and WR were not significantly different between the two groups;
however, the mean aCNR was significantly higher in the low EF
group than in the high EF group.
In DE MR imaging, the aCNR was significantly related to the
LVEF (r =0.49, P =0.0073) (Figure 5). On the other hand, the de-
layed H/M ratio and WR were not significantly related to LVEF
(delayed H/M ratio; r=0.01, P=0.952, WR; r=0.06, P=0.756 )





































Table 1. Mean LVEF, number of slices, aSNR, aCNR, early H/M ratio, de-
layed H/M ratio, and WR in the high LVEF group and low LVEF group.
Note: LVEF =left ventricular ejection f raction
aSNR= average signal-to-noise ra tio per one slice
aCNR= average contrast-to-noise ratio per one slice
MIBG = metaiodobenzylguanidine
H/M= heart/mediastinum
Figure 2. A 51-year-old man with nonischemic dilated cardiomyopathy
(DCM) and high ejection fraction (45%). MR delayed-enhanced image
(repetition time msec/echo time msec/inversion time msec, 9.8/4.4/250;
Flip angle, 25 degrees) shows no focal myocardial DE. The average con-
trast-to-noise ratio (aCNR) of LV myocardium is 1.5
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Table 2 shows the mean aSI of the myocardium, aSNR, aCNR,
delayed H/M ratio, and WR in NYHA I-II and NYHA III-IV
groups. Mean aSI of the myocardium, aSNR, aCNR, and delayed
H/M ratio were not significantly different between the two groups;
however, the mean WR was significantly higher in the NYHA III-
IV (41.7±12.1) groups than in the NYHA I-II groups (27.7±
14.7).
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Figure 3. A 38-year-old man with nonischemic dilated cardiomyopathy
and low ejection fraction (24%). MR delayed-enhanced image (repetition
time msec/echo time msec/inversion time msec, 9.8/4.4/250; Flip angle, 25
degrees) shows diffuse delayed-enhanced areas in the left ventricular myo-
cardium. The aCNR is 13.6
Figure 4. A 50-year-old woman with nonischemic dilated cardiomyopathy
and low ejection fraction (19%). Increased lung uptake and severely re-
duced myocardial uptake are observed on the delayed 123I-MIBG planar
image. The delayed H/M ratio is 1.34. The WR is 60%.
Figure 5. Scatter plots show correlations between LVEF and aCNR. The
aCNR was significantly related to LVEF (r =0.49, P = .0073)
Figure 6. Scatter plots show correlations between LVEF and H/M ratio.
The H/M ratio was not significantly related to LVEF (r =0.01, P = .952)
Figure 7. Scatter plots show correlations between LVEF and WR. The WR
was not significantly related to LVEF (r =0.01, P = .756)
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Discussion
Recently, DE MR imaging is rapidly becoming the standard of
reference for evaluatory myocardial damage with high spatial reso-
lution in various myocardial diseases.13 This technique has also
been used for patients with DCM. In a previous study, 59% of pa-
tients with DCM did not show gadolinium enhancement, although
28% demonstrated longitudinal or patchy midwall enhancement.12
According to a previous report, myocardial fibrosis and disarray
can show enhancement on DE images, but DE related to disarray
is usually faint.12 Hence, in DCM patients, delayed enhancement is
considered to mainly reflect myocardial fibrosis, which may be
caused by inflammation as well as microvascular ischemia.21,22
However, in previous studies, DE of the myocardium was subjec-
tively evaluated based on the presence or absence of focal DE
alone. So far, there are few reports quantitative DE MR imaging.
It is not clear how DE cardiac MR imaging would be useful for
noninvasive evaluation of myocardial contraction function and
clinical severity in patients with DCM.
On the other hand, 123I-MIBG scintigrams are useful for evalua-
tion of LV function in patients with heart failure caused by various
heart diseases including DCM.14-19 In this study, we compared DE
cardiac MR imaging with 123I-MIBG scintigrams for measure-
ment of LV function. We also compared these imaging modalities
between groups divided according to NYHA classification.
Quantification of DE MR imaging
For DE MR imaging, it is important to determine the inversion
time for obtaining optimal image contrast between normal and ab-
normal myocardium. The optimum TI should be adjusted for each
patient to null the signal of normal myocardium.13 However, use of
variable TI makes quantitive assessment of myocardial
enhancement difficult. Moreover, diffuse enhancement of the myo-
cardium cannot be evaluated with this technique.
In this study, we used fixed TI for DE MR imaging, and the
CNR for LV myocardium was calculated using the SI of the del-
toid or trapezius muscle to evaluate diffuse enhancement of the
myocardium objectively. The skeletal muscles have a similar
histological composition, which may be suitable to be used as a
reference ROI. However, further studies are needed to verify
which organ or area is most suitable as a reference ROI.
Usually, ischemic myocardial damage shows segmental distribution
while in DCM, myocardial fibrosis shows diffuse distribution.1,2
Therefore, in DCM patients, it is difficult or impossible to measure
CNR separately in normal and abnormal territories of the myocar-
dium. Therefore, in the present study we used the whole LV myo-
cardium as the ROI for CNR measurement on DE MR images.
123IMIBG imaging
MIBG is an analog of guanethidine that is taken up by uptake-1
as well as norepinephrine followed by storage in adrenalin-related
sympathetic nerve ending. Increased MIBG washuout and reduced
uptake in delayed scan were closely related to cardiac events or
prognosis. It has also been suggested that myocardial MIBG imag-
ing has a great impact on therapeutic management of the failing
heart.14-19
It has been reported that reduced myocardial 123I-MIBG accu-
mulation is correlated with diminished LV function in patients
with heart failure.24,25
DE MR imaging versus 123IMIBG imaging
In this study, the mean aCNR was significantly higher in the low
LVEF group than in the high LVEF group. However, there was no
significant difference between the two groups in 123I-MIBG
scintigrams. In addition, aCNR was significantly related to LVEF
(r =0.49, P =0.0073). On the other hand, delayed H/M ratio and
WR were not significantly related to LVEF. These results suggest
that DE MR imaging may be more useful for evaluating contrac-
tion function than 123I-MIBG scintigrams.
Our study included patients with severe DCM, and it is well
known that early uptake of cardiac MIBG tends to decrease in pa-
tients with severe DCM; this could be a reason why the delayed
H/M ratio and WR were not significantly related to LVEF in our
study.
Our study shows that the mean WR was significantly higher in
NYHA class III-IV groups than NYHA I-II groups. On the other
hand, DE MR imaging was not significantly different between
these two groups. Hence, in patients with DCM, 123I-MIBG find-
ings may more precisely reflect the severity of clinical symptoms
than MR imaging. This result suggests that clinical symptoms are
related not only to contraction function but also to abnormalities of
the myocardial adrenergic nervous system. However, further stud-





































Table 2. Mean LVEF, number of slices, aSNR, aCNR, delayed H/M ratio,
and WR in the NYHA class I-II group and III-IV group.
Note: LVEF=left ventricular ejec tion fraction
aSNR= average signal-to-noise ra tio per one slice
aCNR= average contrast-to-noise ratio per one slice
MIBG = metaiodobenzylguanidine
H/M= heart / mediastinum
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Clinical implications
This study shows that aCNR was significantly related to LVEF,
which may reflect myocardial fibrosis. In previous reports, LVEF
was a powerful and independent predictor of prognosis in patients
with DCM. The severity of left ventricular dysfunction can be
correlated with patients' outcome. Therefore, DE MR imaging is
useful for evaluation of myocardial damage and prediction of prog-
nosis.
Our results also show that the mean WR was significantly higher
in NYHA functional class III-IV than NYHA I-II groups. Previous
studies showed that NYHA functional classes below IV are predic-
tors of prognosis.2,26-31 For, patients who received beta-blocker treat-
ment , NYHA functional class and WR are improved .That is why
123I-MIBG scintigraphy is a very useful tool for evaluating the
myocardial adrenergic nervous system, which is improved in pa-
tients medication.15-18
Study limitations
This study includes several limitations. First, the small number
of patients included in this study was a limitation.
As a second limitation, we evaluated the uptake of MIBG only
in the anterior and inferior areas of the heart, and the MIBG count
was obtained from an average of these two ROIs in each patient.
Therefore our data may not represent overall MIBG uptake. However,
even in normal subjects, the myocardial uptake of MIBG can be
inhomogeneous and reduced in the inferoposterior segment of the
heart. With use of a single, large ROI encompassing an overall
heart, MIBG uptake may be overestimated because the MIBG
count around the heart is included.16
As a third limitation, there may be a problem in quantifying the
cardiac MIBG images. In the present study, 13 patients had an ex-
ceedingly low H/M (<1.7) on the early images. This may introduce
underestimation when drawing ROIs manually on cardiac MIBG
images of patients with heart failure.
Conclusion
DE MR imaging reflects the contraction function of the LV in
patients with DCM, which may reflect myocardial fibrosis. DE
MR imaging may be more useful for evaluation of contraction
function of the LV than 123I-MIBG scintigram images. Analysis
of DE MR imaging, especially aCNR, is expected to provide a po-
tential technique for evaluating LV function and myocardial fibro-
sis in patients with DCM.
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